CFTR chloride channel drug discovery - Inhibitors as antidiarrheals and activators for therapy and cystic fibrosis

Current Pharmaceutical Design

Volumn 12, Issue 18, 2006, Pages 2235-2247

  Verkman, A S ^a   Lukacs, Gergely L ^b   Galietta, Luis J V ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

CFTR; Chloride channel; Cystic fibrosis; Diarrhea; Drug discovery; High throughput screening; Inhibitor; Polycystic kidney disease

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; 5 NITRO 2 (3 PHENYLPROPYLAMINO)BENZOIC ACID; ANTIDIARRHEAL AGENT; APIGENIN; BENZOTHIOPHENE DERIVATIVE; CHLORIDE CHANNEL; CHLORIDE CHANNEL BLOCKING AGENT; CHOLERA TOXIN; CYCLIC AMP; EFENAMIC ACID; ENTEROTOXIN; FLUFENAMIC ACID; FORSKOLIN; GENISTEIN; GLIBENCLAMIDE; HALIDE; HYDRAZIDE DERIVATIVE; MUTANT PROTEIN; ORAL ANTIDIABETIC AGENT; PHENYLGLYCINE; PHOSPHODIESTERASE INHIBITOR; SULFONAMIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CHRONIC LUNG DISEASE; CYSTIC FIBROSIS; DEATH; DIARRHEA; DRUG BINDING SITE; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; FLUID TRANSPORT; FLUORESCENCE ANALYSIS; GENETIC DISORDER; HIGH THROUGHPUT SCREENING; HUMAN; INTESTINE EPITHELIUM; KIDNEY POLYCYSTIC DISEASE; LUNG ALVEOLUS EPITHELIUM; LUNG INFECTION; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RODENT; STRUCTURE ANALYSIS; TESTIS;

ANIMALS; ANTIDIARRHEALS; BIOSENSING TECHNIQUES; CELL LINE; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIARRHEA; DRUG DESIGN; GLYCINE; HUMANS; INTESTINAL MUCOSA; ION CHANNEL GATING; LIGANDS; LUMINESCENT PROTEINS; MUTATION; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SULFONAMIDES; THIAZOLIDINEDIONES; TRANSFECTION;

EID: 33745120825     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777585148     Document Type: Article

References (52)

1. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059-65.
2. Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev 1999; 79: S215-55.
3. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79: S23-45.
4. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606.
5. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358: 761-4.
6. Kopito RR. Biosynthesis and degradation of CFTR. Physiol Rev 1999; 79: S167-73.
7. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, et al. Altered chloride ion channel kinetics associated with the deltaF508 cystic fibrosis mutation. Nature 1991; 354: 526-8.
8. Haws CM, Nepomuceno IB, Krouse ME, Wakelee H, Law T, Xia Y, et al. DeltaF508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am J Physiol 1996; 270: C1544-55.
9. Gabriel SE, Brigman KN, Koller BH, Boucher RC, Stutts MJ. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 1994; 266: 107-9.
10. Thiagarajah JR, Verkman AS. New drug targets for cholera therapy. Trends Pharmacol Sci 2005; 26: 172-5.
11. Verkman AS. Development and biological applications of chloridesensitive fluorescent indicators. Am J Physiol 1990; 259: C375-88.
12. Mansoura MK, Biwersi J, Ashlock MA, Verkman AS. Fluorescent chloride indicators to assess the efficacy of CFTR cDNA delivery. Hum Gene Ther 1999; 10: 861-75.
13. Jayaraman S, Haggie P, Wachter RM, Remington SJ, Verkman AS. Mechanism and cellular applications of a green fluorescent proteinbased halide sensor. J Biol Chem 2000; 275: 6047-50.
14. Galietta LJ, Haggie PM, Verkman AS. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett 2001; 499: 220-4.
15. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol 2001; 281: C1734-42.
16. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, et al. Nanomolar affinity small molecule correctors of defective deltaF508-CFTR chloride channel gating. J Biol Chem 2003; 278: 35079-85.
17. Illsley NP, Verkman AS. Membrane chloride transport measured using a chloride-sensitive fluorescent probe. Biochemistry 1987; 26: 1215-9.
18. Jayaraman S, Teitler L, Skalski B, Verkman AS. Long-wavelength iodide-sensitive fluorescent indicators for measurement of functional CFTR expression in cells. Am J Physiol 1999; 277: C1008-18.
19. Tsien RY. The green fluorescent protein. Annu Rev Biochem 1998; 67: 509-44.
20. Ormo M, Cubitt AB, Kallio K, Gross LA, Tsien RY, Remington SJ. Crystal structure of the Aequorea victoria green fluorescent protein. Science 1996; 273: 1392-5.
21. Kneen M, Farinas J, Li Y, Verkman AS. Green fluorescent protein as a noninvasive intracellular pH indicator. Biophys J 1998; 74: 1591-9.
22. Llopis J, McCaffery JM, Miyawaki A, Farquhar MG, Tsien RY. Measurement of cytosolic, mitochondrial, and Golgi pH in single living cells with green fluorescent proteins. Proc Natl Acad Sci USA 1998; 95: 6803-8.
23. Wachter RM, Elsliger MA, Kallio K, Hanson GT, Remington SJ. Structural basis of spectral shifts in the yellow-emission variants of green fluorescent protein. Structure 1998; 6: 1267-77.
24. Wachter RM, Yarbrough D, Kallio K, Remington SJ. Crystallographic and energetic analysis of binding of selected anions to the yellow variants of green fluorescent protein. J Mol Biol 2000; 301: 157-71.
25. Dawson DC, Smith SS, Mansoura MK. CFTR: mechanism of anion conduction. Physiol Rev 1999; 79: S47-75.
26. Galietta LJ, Springsteel MF, Eda M, Niedzinski EJ, By K, Haddadin MJ, et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001; 276: 19723-8.
27. O'Donnell EK, Sedlacek RL, Singh AK, Schultz BD. Inhibition of enterotoxin-induced porcine colonic secretion by diarylsulfonylureas in vitro. Am J Physiol 2000; 279: G1104-12.
28. Zhou Z, Hu S, Hwang TC. Probing an open CFTR pore with organic anion blockers. J Gen Physiol 2002; 120: 647-62.
29. Schultz BD, Singh AK, Devor DC, Bridges RJ. Pharmacology of CFTR chloride channel activity. Physiol Rev 1999; 79: S109-44.
30. - channel by two closely related arylaminobenzoates. J Gen Physiol 1993; 102: 1-23.
31. Linsdell P. Location of a common inhibitor binding site in the cytoplasmic vestibule of the cystic fibrosis transmembrane conductance regulator chloride channel pore. J Biol Chem 2005; 280: 8945-50.
32. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, et al. Thiazolidinone CFTR inhibitor identified by highthroughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110: 1651-8.
33. Sonawane ND, Muanprasat C, Nagatani R Jr, Song Y, Verkman AS. In vivo pharmacology and antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents. J Pharm Sci 2005; 94: 134-43.
34. Thiagarajah JR, Broadbent T, Hsieh E, Verkman AS. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 2004; 126: 511-9.
35. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, Verkman AS. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol 2004; 124: 125-37.
36. Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, Galietta LJ. Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. FEBS Lett 2004; 558: 52-6.
37. Sonawane ND, Hu H, Muanprasat C, Verkman AS. Luminally-active non-absorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. FASEB J 2006; 20: 130-132.
38. Drumm ML, Wilkinson DJ, Smit LS, Worrell RT, Strong TV, Frizzell RA, et al. Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 1991; 254: 1797-9.
39. Hwang TC, Wang F, Yang IC, Reenstra WW. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 1997; 273: C988-98.
40. Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol 1999; 277: C833-9.
41. Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran O, Galietta LJ, et al. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 2002; 277: 37235-41.
42. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, et al. Phenylglycine and sulfonamide correctors of defective deltaF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67: 1797-807.
43. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (deltaF508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 1994; 13: 6076-86.
44. Du K, Sharma M, Lukacs GL. The deltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 2005; 12: 17-25.
45. Sharma M, Benharouga M, Hu W, Lukacs GL. Conformational and temperature-sensitive stability defects of the deltaF508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J Biol Chem 2001; 276: 8942-50.
46. Gentzsch M, Chang XB, Cui L, Wu Y, Ozols VV, Choudhury A, et al. Endocytic trafficking routes of wild type and deltaF508 cystic fibrosis transmembrane conductance regulator. Mol Biol Cell 2004; 15: 2684-96.
47. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996; 271: 635-8.
48. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing deltaF508-CFTR. J Clin Invest 1997; 100: 2457-65.
49. Pedemonte N, Lukacs, GL, Du K, Caci E, Zegarra-Moran O, Gailetta LJ, et al. Small molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115: 2564-2571.
50. Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005; 11(10): 1291-300.
51. Suh KS, Yuspa SH. Intracellular chloride channels: critical mediators of cell viability and potential targets for cancer therapy. Curr Pharm Des 2005; 11(21): 2753-64.
52. Vogt PH. Molecular genetics of human male infertility: from genes to new therapeutic perspectives. Curr Pharm Des 2004; 10(5): 471-500.